Overall serious adverse events · people who smoke
Preloading nicotine replacement therapy (NRT) showed no clear difference in overall serious adverse events compared with standard‐use NRT (low certainty).
1 finding from 1 review
Overall rate of adverse events · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in overall rate of adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Overall adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes overall adverse events compared with morning dosing regimen (very low certainty).
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · adults with Major Depressive Disorder
Amitriptyline probably leads to higher overall tolerability Drop‐out due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Overall adverse events 5 weeks · adults with seasonal affective disorder
It is very uncertain whether fluoxetine changes overall adverse events 5 weeks compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Incidence of adverse events ‐ overall · children with HIV infection aged 12 years and under
The intervention showed no clear difference in incidence of adverse events ‐ overall (moderate certainty).
1 finding from 1 review
Overall local/injection site adverse events · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall local/injection site adverse events · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall local/injection site adverse events at 15‐day · 10‐ to 26‐year‐old males
Three doses HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with control (high certainty).
1 finding from 1 review
Overall local/injection site adverse events at 15‐day · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with quadrivalent HPV vaccine (high certainty).
1 finding from 1 review